CHK1 inhibition as a strategy for targeting fanconi anemia (FA) DNA repair pathway deficient tumors

Molecular Cancer

Volumn 8, Issue , 2009, Pages

  Chen, Clark C ^a,b   Kennedy, Richard D ^a   Sidi, Samuel ^a   Look, A Thomas ^a   D'Andrea, Alan ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; 7 HYDROXYSTAUROSPORINE; CHECKPOINT KINASE 1; CISPLATIN; MORPHOLINE; SMALL INTERFERING RNA; CARBAZOLE DERIVATIVE; PROTEIN KINASE; PROTEIN KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CHROMOSOME BREAKAGE; CONTROLLED STUDY; DNA REPAIR; DNA STRAND; DRUG POTENTIATION; EMBRYO; ENZYME INHIBITION; FANCONI ANEMIA; GENE ACTIVATION; GENE IDENTIFICATION; GENE SILENCING; HUMAN; HUMAN CELL; NONHUMAN; ZEBRA FISH; ANIMAL; ANIMAL EMBRYO; DNA DAMAGE; GENETICS; HELA CELL; METABOLISM; NEOPLASM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

DANIO RERIO;

ANIMALS; CARBAZOLES; CELL DEATH; CISPLATIN; DNA DAMAGE; DNA REPAIR; EMBRYO, NONMAMMALIAN; FANCONI ANEMIA; GENE SILENCING; HELA CELLS; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SIGNAL TRANSDUCTION; ZEBRAFISH;

EID: 65449142073     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-8-24     Document Type: Article

References (44)

1. Lengauer C Kinzler KW Vogelstein B Genetic instabilities in human cancers Nature 1998, 396:643-649. 10.1038/25292 9872311
2. Kastan MB Bartek J Cell-cycle checkpoints and cancer Nature 2004, 432:316-323. 10.1038/nature03097 15549093
3. Kennedy RD D'Andrea AD DNA repair pathways in clinical practice: Lessons from pediatric cancer susceptibility syndromes J Clin Oncol 2006, 24:3799-3808. 10.1200/JCO.2005.05.4171 16896009
4. Wang W Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins Nat Rev Genet 2007, 10:735-748. 10.1038/nrg2159
5. Chen CC Taniguchi T D'Andrea A The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents J Mol Med 2007, 85:497-509. Epub 2007 Jan 2013. 10.1007/s00109-006-0153-2 17221219
6. Taniguchi T Tischkowitz M Ameziane N Hodgson SV Mathew CG Joenje H Mok SC D'Andrea AD Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors Nat Med 2003, 9:568-574. 10.1038/ nm852 12692539
7. Narayan G Arias-Pulido H Nandula SV Basso K Sugirtharaj DD Vargas H Mansukhani M Villella J Meyer L Schneider A Gissmann L Durst M Pothuri B Murty VV Promoter hypermethylation of FANCF: Disruption of Fanconi Anemia-BRCA pathway in cervical cancer Cancer Res 2004, 64:2994-2997. 10.1158/0008-5472.CAN-04-0245 15126331
8. Marsit CJ Liu M Nelson HH Posner M Suzuki M Kelsey KT Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: Implications for treatment and survival Oncogene 2003, 23:10000-1004. 10.1038/ sj.onc.1207256
9. Tischkowitz M Ameziane N Waisfisz Q De Winter JP Harris R Taniguchi T D'Andrea A Hodgson SV Mathew CG Joenje H Bi-allelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia Br J Haematol 2003, 123:469-471. 10.1046/j.1365-2141.2003.04640.x 14617007
10. Taniguchi T D'Andrea AD Molecular pathogenesis of Fanconi anemia: Recent progress Blood 2006, 107:4223-4233. Epub 2006 Feb 4221. 10.1182/ blood-2005-10-4240 16493006
11. Kennedy RD Chen CC Stuckert P Archila EM De la Vega MA Moreau LA Shimamura A D'Andrea AD Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated J Clin Invest 2007, 117:1440-1449. 1847538 17431503 10.1172/JCI31245
12. Latt SA Kaiser TN Lojewski A Dougherty C Juergens L Brefach S Sahar E Gustashaw K Schreck RR Powers M Lalande M Cytogenetic and flow cytometric studies of cells from patients with Fanconi's anemia Cytogenet Cell Genet 1982, 33:133-138. 10.1159/000131737 7116934
13. Kupfer GM D'Andrea AD The effect of the Fanconi anemia polypeptide, FAC, upon p53 induction and G2 checkpoint regulation Blood 1996, 88:1019-1025. 8704210
14. Pulsipher M Kupfer GM Naf D Suliman A Lee JS Jakobs P Grompe M Joenje H Sieff C Guinan E Mulligan R D'Andrea AD Subtyping analysis of Fanconi anemia by immunoblotting and retroviral gene transfer Mol Med 1998, 4:468-479. 2230330 9713825
15. Andreassen; PR D'Andrea AD Taniguchi T ATR couples FANCD2 monoubiquitination to the DNA-damage response Genes Dev 2004, 18:1958-1963. 514175 15314022 10.1101/gad.1196104
16. Bartek J Lukas J Chk1 and Chk2 kinases in checkpoint control and cancer Cancer Cell 2003, 3:421-429. 10.1016/S1535-6108(03)00110-7 12781359
17. Tse AN Carvajal R Schwartz GK Targeting checkpoint kinase 1 in cancer therapeutics Clin Cancer Res 2007, 13:1955-1960. 10.1158/ 1078-0432.CCR-06-2793 17404075
18. Zhou BB Bartek J Targeting the checkpoint kinases: Chemosensitization versus chemoprotection Nat Rev Cancer 2004, 4:216-225. 10.1038/nrc1296 14993903
19. Lara PN Jr Mack PC Synold T Frankel P Longmate J Gumerlock PH Doroshow JH Gandara DR The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: A California cancer consortium phase I pharmacokinetic and molecular correlative trial Clin Cancer Res 2005, 11:4444-4450. 10.1158/1078-0432.CCR-04-2602 15958629
20. Kortmansky J Shah MA Kaubisch A Weyerbacher A Yi S Tong W Sowers R Gonen M O'Reilly E Kemeny N Ilson DI Saltz LB Maki RG Kelsen DP Schwartz GK Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors J Clin Oncol 2005, 23:1875-1884. 10.1200/JCO.2005.03.116 15699481
21. Hotte SJ Oza A Winquist EW Moore M Chen EX Brown S Pond GR Dancey JE Hirte HW Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: A Princess Margaret Hospital Phase II Consortium study Ann Oncol 2006, 17:334-340. 10.1093/annonc/mdj076 16284058
22. Sampath D Cortes J Estrov Z Du M Shi Z Andreeff M Gandhi V Plunkett W Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial Blood 2006, 107:2517-2524. 1895741 16293603 10.1182/ blood-2005-08-3351
23. Bain J Plater L Elliott M Shpiro N Hastie CJ McLauchlan H Klevernic I Arthur JS Alessi DR Cohen P The selectivity of protein kinase inhibitors: A further update Biochem J 2007, 408:297-315. 2267365 17850214 10.1042/BJ20070797
24. Kohn EA Yoo CJ Eastman A The protein kinase C inhibitor Gö6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints Cancer Res 2003, 63:31-35. 12517773
25. Seynaeve CM Kazanietz MG Blumberg PM Sausville EA Worland PJ Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue Molecular Pharmacology 1994, 45:1207-1214. 8022414
26. MacKeigan JP Murphy LO Blenis J Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance Nature Cell Biology 2005, 7:591-600. 10.1038/ncb1258 15864305
27. Yarden RI Pardo-Reoyo S Sgagias M Cowan KH Brody LC BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage Nat Genet 2002, 30:285-289. 10.1038/ng837 11836499
28. Kennedy RD D'Andrea AD The Fanconi Anemia/BRCA pathway: New faces in the crowd Genes Dev 2005, 19:2925-2940. 10.1101/gad.1370505 16357213
29. Taniguchi T Garcia-Higuera I Andreassen PR Gregory RC Grompe M D'Andrea AD S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51 Blood 2002, 100:2414-2420. 10.1182/ blood-2002-01-0278 12239151
30. Syljuasen RG Sorensen CS Hansen LT Fugger K Lundin C Johansson F Helleday T Sehested M Lukas J Bartek J Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage Mol Cell Biol 2005, 25:3553-3562. 1084285 15831461 10.1128/MCB.25.9.3553-3562.2005
31. Liu TX Howlett NG Deng M Langenau DM Hsu K Rhodes J Kanki JP D'Andrea AD Look AT Knockdown of zebrafish Fancd2 causes developmental abnormalities via p53-dependent apoptosis Dev Cell 2003, 5:903-914. 10.1016/ S1534-5807(03)00339-3 14667412
32. Sidi S Sanda T Kennedy RD Hagen AT Jette CA Hoffmans R Pascual J Imamura S Kishi S Amatruda JF Kanki JP Green DR D'Andrea AA Look AT Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3 Cell 2008, 133:864-877. 10.1016/ j.cell.2008.03.037 18510930
33. Chou TC Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol Rev 2006, 58:621-681. 10.1124/pr.58.3.10 16968952
34. Sha SK Sato T Kobayashi H Ishigaki M Yamamoto S Sato H Takada A Nakajyo S Mochizuki Y Friedman JM Cheng FC Okura T Kimura R Kufe DW Vonhoff DD Kawabe T Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint Mol Cancer Ther 2007, 6:147-153. 10.1158/ 1535-7163.MCT-06-0371 17237275
35. Zabludoff SD Deng C Grondine MR Sheehy AM Ashwell S Caleb BL Green S Haye HR Horn CL Janetka JW Liu D Mouchet E Ready S Rosenthal JL Queva C Schwartz GK Taylor KJ Tse AN Walker GE White AM AZD a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies Molecular Cancer Therapeutics 7762, 7:2955-2966. 10.1158/1535-7163.MCT-08-0492
36. Liu Q Guntuku S Cui XS Matsuoka S Cortez D Tamai K Luo G Carattini-Rivera S DeMayo F Bradley A Donehower LA Elledge SJ Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint Genes Dev 2000, 14:1448-1459. 316686 10859164 10.1101/gad.840500
37. Garcia-Higuera I Kuang Y Denham J D'Andrea AD The fanconi anemia proteins FANCA and FANCG stabilize each other and promote the nuclear accumulation of the Fanconi anemia complex Blood 2000, 96:3224-3230. 11050007
38. Garcia-Higuera I Taniguchi T Ganesan S Meyn MS Timmers C Hejna J Grompe M D'Andrea AD Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway Mol Cell 2001, 7:249-262. 10.1016/S1097-2765(01)00173-3 11239454
39. Naf D Kupfer GM Suliman A Lambert K D'Andrea AD Functional activity of the fanconi anemia protein FAA requires FAC binding and nuclear localization Mol Cell Biol 1998, 18:5952-5960. 109181 9742112
40. Stewart GS Wang B Bignell CR Taylor AM Elledge SJ MDC1 is a mediator of the mammalian DNA damage checkpoint Nature 2003, 421:961-966. 10.1038/ nature01446 12607005
41. Wang X Kennedy RD Ray K Stuckert P Ellenberger T D'Andrea AD Chk1-mediated phosphorylation of FANCE is required for the Fanconi anemia/BRCA pathway Mol Cell Biol 2007, 27:3098-3108. 1899922 17296736 10.1128/MCB.02357-06
42. Kupfer GM Naf D Suliman A Pulsipher M D'Andrea AD The Fanconi anaemia proteins, FAA and FAC, interact to form a nuclear complex Nat Genet 1997, 17:487-490. 10.1038/ng1297-487 9398857
43. Siddique MA Nakanishi K Taniguchi T Grompe M D'Andrea AD Function of the Fanconi anemia pathway in Fanconi anemia complementation group F and D1 cells Exp Hematol 2001, 29:1448-1455. 10.1016/S0301-472X(01)00754-8 11750104
44. Yang Y Kuang Y Montes De Oca R Hays T Moreau L Lu N Seed B D'Andrea AD Targeted disruption of the murine Fanconi anemia gene, Fancg/Xrcc9 Blood 2001, 98:3435-3440. 10.1182/blood.V98.12.3435 11719385